See more : Kandenko Co.,Ltd. (1942.T) Income Statement Analysis – Financial Results
Complete financial analysis of Athersys, Inc. (ATHX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Athersys, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- AB Volvo (publ) (VLVLY) Income Statement Analysis – Financial Results
- Bloomsbury Publishing Plc (BMY.L) Income Statement Analysis – Financial Results
- BlackRock MuniYield Fund, Inc. (MYD) Income Statement Analysis – Financial Results
- Xebio Holdings Co., Ltd. (8281.T) Income Statement Analysis – Financial Results
- Shimizu Corporation (SHMUF) Income Statement Analysis – Financial Results
Athersys, Inc. (ATHX)
About Athersys, Inc.
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.33M | 5.51M | 1.43M | 5.52M | 23.74M | 2.84M | 16.24M | 10.30M | 286.00K | 755.00K | 7.38M | 10.34M | 8.94M | 2.16M | 3.11M | 3.26M | 0.00 | 3.60M | 0.00 | 2.15M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | -554.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 5.33M | 5.51M | 1.43M | 5.52M | 24.29M | 2.84M | 16.24M | 11.95M | 1.62M | 2.44M | 8.71M | 10.34M | 8.94M | 2.16M | 3.11M | 3.26M | 0.00 | 3.60M | 0.00 | 2.15M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 102.33% | 100.00% | 100.00% | 116.02% | 567.48% | 322.91% | 117.99% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 0.00% | 100.00% |
| Research & Development | 65.03M | 71.08M | 62.99M | 39.05M | 38.66M | 27.84M | 24.84M | 21.32M | 23.37M | 20.48M | 19.64M | 18.93M | 14.78M | 11.92M | 16.50M | 15.82M | 0.00 | 12.58M | 0.00 | 13.68M |
| General & Administrative | 15.88M | 20.07M | 15.89M | 11.38M | 10.44M | 8.47M | 7.84M | 7.54M | 6.91M | 6.07M | 4.75M | 4.92M | 5.39M | 5.62M | 5.48M | 7.98M | 1.51K | 3.76M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 15.88M | 20.07M | 15.89M | 11.38M | 10.44M | 8.47M | 7.84M | 7.54M | 6.91M | 6.07M | 4.75M | 4.92M | 5.39M | 5.62M | 5.48M | 7.98M | 1.51K | 3.76M | 0.00 | 0.00 |
| Other Expenses | 1.42M | 1.43M | 882.00K | 582.00K | 762.00K | 314.00K | 209.00K | -61.00K | 86.00K | 38.00K | -1.17M | 278.00K | 284.00K | 233.00K | 218.00K | 283.00K | 0.00 | 982.00K | 0.00 | 22.19M |
| Operating Expenses | 82.33M | 92.57M | 79.76M | 51.01M | 49.40M | 36.13M | 31.95M | 27.47M | 29.30M | 25.21M | 23.38M | 24.12M | 20.45M | 17.77M | 22.20M | 24.08M | 1.51K | 17.32M | 0.00 | 35.86M |
| Cost & Expenses | 82.33M | 92.57M | 79.76M | 51.01M | 49.40M | 36.13M | 31.95M | 27.47M | 29.30M | 25.21M | 23.38M | 24.12M | 20.45M | 17.77M | 22.20M | 24.08M | 1.51K | 17.32M | 0.00 | 35.86M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 34.00K | 85.00K | 203.00K | 375.00K | 1.15M | 1.59M | 0.00 | 317.00K | 0.00 | 644.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 243.00K | 0.00 | 0.00 | 94.00K | 1.26M | 0.00 | 964.00K | 0.00 | 135.00K |
| Depreciation & Amortization | 1.42M | 1.43M | 890.00K | 698.00K | 855.00K | 684.00K | 382.00K | 267.00K | 360.00K | 346.00K | 320.00K | 278.00K | 284.00K | 233.00K | 218.00K | 231.00K | 0.00 | 938.00K | 0.00 | 1.80M |
| EBITDA | -75.59M | -85.63M | -77.44M | -44.79M | -25.42M | -33.33M | -15.03M | -17.17M | -29.01M | -24.46M | -16.00M | -20.82M | -11.23M | -15.62M | -18.91M | -20.82M | -1.51K | -12.50M | 0.00 | -30.83M |
| EBITDA Ratio | -1,419.51% | -1,552.97% | -5,407.96% | -811.85% | -107.11% | -1,172.25% | -95.15% | -171.64% | -12,322.73% | -2,355.89% | -245.05% | -130.04% | -124.82% | -706.62% | -609.44% | -677.70% | 0.00% | -347.72% | 0.00% | -1,432.57% |
| Operating Income | -77.01M | -87.06M | -78.33M | -45.49M | -25.05M | -33.28M | -15.03M | -17.17M | -29.01M | -24.46M | -16.00M | -13.78M | -11.51M | -15.62M | -19.09M | -20.82M | -1.51K | -13.97M | 0.00 | -34.78M |
| Operating Income Ratio | -1,446.18% | -1,578.85% | -5,470.11% | -824.51% | -105.51% | -1,170.70% | -92.54% | -166.74% | -10,144.06% | -3,239.34% | -216.82% | -133.22% | -128.77% | -723.25% | -614.88% | -638.50% | 0.00% | -388.49% | 0.00% | -1,616.36% |
| Total Other Income/Expenses | 4.48M | 103.00K | -433.00K | 906.00K | 762.00K | 1.04M | -348.00K | 711.00K | 6.68M | -6.29M | 1.27M | 34.00K | 134.00K | 249.00K | 1.10M | -3.57M | -52.00K | -233.00K | 0.00 | -1.08M |
| Income Before Tax | -72.53M | -86.96M | -78.77M | -44.58M | -24.28M | -32.24M | -15.37M | -16.46M | -22.34M | -30.74M | -14.74M | -24.39M | -11.38M | -17.99M | -17.99M | -24.39M | 0.00 | -14.20M | 0.00 | -35.86M |
| Income Before Tax Ratio | -1,362.14% | -1,576.99% | -5,500.35% | -808.08% | -102.30% | -1,134.05% | -94.68% | -159.84% | -7,809.44% | -4,071.92% | -199.66% | -235.74% | -127.27% | -833.35% | -579.45% | -748.01% | 0.00% | -394.97% | 0.00% | -1,666.36% |
| Income Tax Expense | -4.47M | 0.00 | 0.00 | 0.00 | 762.00K | -728.00K | -37.00K | -38.00K | -253.00K | 6.32M | -2.44M | -34.00K | -134.00K | -249.00K | -1.10M | -1.84M | 1.51K | 924.00K | 0.00 | -547.00K |
| Net Income | -68.06M | -86.96M | -78.77M | -44.58M | -24.28M | -32.24M | -15.34M | -16.42M | -22.08M | -30.74M | -14.74M | -13.75M | -11.38M | -15.37M | -17.99M | -18.93M | -1.51K | -14.60M | 0.00 | -33.16M |
| Net Income Ratio | -1,278.14% | -1,576.99% | -5,500.35% | -808.08% | -102.30% | -1,134.05% | -94.45% | -159.47% | -7,720.98% | -4,071.92% | -199.66% | -132.89% | -127.27% | -711.72% | -579.45% | -580.55% | 0.00% | -405.98% | 0.00% | -1,540.94% |
| EPS | -5.70 | -9.69 | -10.50 | -7.35 | -4.44 | -7.19 | -4.53 | -5.00 | -7.17 | -13.33 | -11.31 | -14.79 | -15.03 | -20.29 | -23.76 | -43.77 | -0.01 | -83.61 | 0.00 | -205.21 |
| EPS Diluted | -5.70 | -9.69 | -10.50 | -7.35 | -4.44 | -7.19 | -4.53 | -4.96 | -7.03 | -13.33 | -11.31 | -14.79 | -15.03 | -20.29 | -23.76 | -43.77 | -0.01 | -83.61 | 0.00 | -205.21 |
| Weighted Avg Shares Out | 11.95M | 8.97M | 7.50M | 6.07M | 5.47M | 4.48M | 3.39M | 3.29M | 3.08M | 2.31M | 1.30M | 929.56K | 757.19K | 757.14K | 757.12K | 432.45K | 175.53K | 174.62K | 179.28K | 161.59K |
| Weighted Avg Shares Out (Dil) | 11.95M | 8.97M | 7.50M | 6.07M | 5.47M | 4.48M | 3.39M | 3.31M | 3.14M | 2.31M | 1.30M | 929.56K | 757.19K | 757.14K | 757.12K | 432.45K | 175.53K | 174.62K | 179.28K | 161.59K |
Athersys Provides MultiStem Clinical Update
CLEVELAND--( BUSINESS WIRE )--Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, today provided an update on ongoing clinical trials with MultiStem for the treatment of patients following hemorrhagic trauma (MATRICS-1) and for the...
Athersys Appoints Joseph Nolan to Its Board of Directors
CLEVELAND--( BUSINESS WIRE )--Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today the appointment of Joseph “Joe” Nolan to its Board of Directors, effective January 4, 2023. Mr. Nolan is an experienced...
Athersys, Inc. (ATHX) Q3 2022 Earnings Call Transcript
Athersys, Inc. (NASDAQ:ATHX ) Q3 2022 Earnings Conference Call November 15, 2022 11:00 AM ET Company Participants Ellen Gurley – Corporate Communications and Investor Relations Dan Camardo – Chief Executive Officer Kasey Rosado – Interim Chief Financial Officer Conference Call...
Athersys Reports Third Quarter 2022 Financial Results and Provides Business Update
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three and nine months ended September 30, 2022 and provided a business update. Third quarter 2022 Corporate and Operational Highlights: Corporate Restructuring Raised gross proceeds of $12.0 million...
Athersys Reports Third Quarter 2022 Financial Results and Provides Business Update
CLEVELAND--( BUSINESS WIRE )--Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three and nine months ended September 30, 2022 and provided a business update.
Athersys to Present at Challenges and Opportunities for Mesenchymal Stem Cells Digital Conference and Participate in A.G.P.'s Biotech Conference
CLEVELAND--( BUSINESS WIRE )--Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today its participation in two November conferences, the Challenges and Opportunities for Mesenchymal Stem Cells digital conference being held November 17-18,...
Athersys, Inc. Announces Closing of $5.5 Million Confidentially Marketed Public Offering
CLEVELAND--( BUSINESS WIRE )--Athersys, Inc. (Nasdaq: ATHX) today announced the closing of its previously announced confidentially marketed public offering with healthcare-focused U.S. institutional investors for the purchase of 5,004,545 shares of the Company's common stock (or common stock equivalents in...
Athersys, Inc. Announces Pricing of $5.5 Million Public Offering
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX) (“Athersys” or the “Company”) today announced the pricing of its previously announced "best efforts" public offering of 5,004,545 shares of common stock (or common stock equivalents) and warrants to purchase 10,009,090 shares of common stock...
Athersys, Inc. Announces Proposed Public Offering
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX) (“Athersys” or the “Company”) today announced that it intends to offer and sell shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase common stock, subject to market and...
Athersys to Host Third Quarter Financial Results Call
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX) will be hosting a conference call on Thursday, November 10, 2022, at 4:30 PM Eastern Time to review its third quarter 2022 financial results.
Source: https://incomestatements.info
Category: Stock Reports